Abstract. Acute lymphoblastic leukemia (ALL) is a disseminated malignancy of B-or Tlymphoblasts which imposes a rapid and accurate diagnostic process to support an optimal riskoriented therapy and thus increase the curability rate. The need for a precise diagnostic algorithm is underlined by the awareness that both ALL therapy and related success rates may vary greatly between ALL subsets, from standard chemotherapy in patients with standard-risk ALL, to allotransplantation (SCT) and targeted therapy in high-risk patients and cases expressing suitable biological targets, respectively. This review summarizes how best to identify ALL and the most relevant ALL subsets.
Introduction.
Current standards for acute lymphoblastic leukemia (ALL) diagnosis integrate the study of cell morphology, immunophenotype and genetics/cytogenetics as detailed in the 2008 WHO classification of lymphoid neoplasms. 1 The classification originally suggested by the FAB group is no longer followed. 2, 3 The FAB classification was clinically useful since it permitted recognition of probable Burkitt lymphoma in leukemic phase, but it has now been replaced by the WHO classification. Lymphoid neoplasms are assigned, in the most recent WHO classification, to two principal categories: neoplasms derived from B-and T-lineage lymphoid precursors and those derived from mature B, T or NK cells. ALL belongs to the first of these major groups, designated B-or T-lymphoblastic leukemia/lymphoma 4 and including three principal categories: Blymphoblastic leukemia/lymphoma not otherwise specified, B-lymphoblastic leukemia/lymphoma with recurrent cytogenetic alterations and T-lymphoblastic leukemia/lymphoma. The designation of leukemia/lymphoma reflects the principle that these neoplasms should be classified on the basis of their biological and molecular characteristics, regardless of the sites of involvement. The leukemic variant shows diffuse involvement of the peripheral blood and the bone marrow, while lymphoma is confined to nodal or extranodal sites, with no or minimal involvement of the bone marrow. In the leukemic form, by definition, the bone marrow must contain at least 20% blast cells. A purely leukemic presentation is most typical of Blineage ALL (85%), while cases of T-lineage disease often present with an associated lymphomatous mass in the mediastinum or other sites.
Diagnostic Morphology and Cytochemistry.
A morphological bone marrow assessment represents the first step in the diagnostic pathway, for the primary diagnosis of ALL and for the differentiation from acute myeloid leukemia (AML), 5 since ALL, by definition, always presents with bone marrow involvement. Table  1 6 shows the morphological criteria that are useful for distinguishing between myeloblasts and lymphoblasts, however remembering the limits of morphology in ALL, for which flow cytometry analysis represents the diagnostic gold standard for both the identification of cell lineage and the definition of subset. The morphology of leukemic cells in the peripheral blood can be significantly different from that of the bone marrow, which is always indispensable.
From the morphological point of view, there are no reproducible criteria to distinguish between B-and Tlineage ALL. It can also be difficult to distinguish Blineage lymphoblasts from normal B-lineage lymphoid precursors, known as hematogones, which are observed in the peripheral blood in various conditions, including primary myelofibrosis and in children in the phase of recovery following chemotherapy. 7 Hematogones typically have an even higher nucleocytoplasmic ratio than lymphoblasts, with more homogeneous chromatin and a complete absence of visible nucleoli. Hematogones can also express the CD10 antigen, but can be distinguished from blast cells of B ALL by other immunophenotypic features, being characterised by regular, orderly acquisition and loss of B-lineage antigens; they can also be distinguished from mature lymphocytes by their weak expression of CD45 and, sometimes, by the expression of CD34. 7 The bone marrow morphology of ALL is however quite variable as previously indicated in the FAB classification (Figures 1-2) . Rare morphological variants are: ALL with "hand-mirror cells", i.e. the shape of the cells resembles a hand mirror or a tennis racquet ( Figure 2A) ; granular ALL, with presence of azurophilic cytoplasmic granules which vary in number, size and shape. Cytochemically, these blasts have negative peroxidase reactions and variable periodic acid-Schiff (PAS) positivity; Sudan black B is sometimes weakly positive; 8 ALL with mature cells that are nearly indistinguishable from mature lymphoid neoplasms and require expert observers for accurate morphological identification; 9 ALL associated with hypereosinophilia ( Figure 2B ). By definition, ALL blasts are negative for myeloperoxidase (MPO) ( Figure 2C ) and other myeloid cytochemical reactions. According to the FAB criteria, acute More recently, novel MFC strategies were developed by the EuroFlow consortium to ensure accurate methodologies through all MFC steps, in order to guarantee the reproducibility of diagnostic tests. 12, 13 To summarize the diagnostic issue, roughly 75-80% of cases of adult ALL are of B-cell lineage and 20-25% belong to the T-cell lineage.
Immunophenotype of B-lineage ALL. In B-lineage ALL the most important markers for diagnosis, differential diagnosis and subclassification are CD19, CD20, CD22, CD24, and CD79a. The earliest Blineage markers are CD19, CD22 (membrane and cytoplasm) and CD79a.
14,15 A positive reaction for any two of these three markers, without further differentiation markers, identifies pro-B ALL (EGIL B-I subtype) ( Figure 3A) . The presence of CD10 antigen (CALLA) defines the "common" ALL subgroup (EGIL B-II subtype). Cases with additional identification of cytoplasmic heavy mu chain constitute the pre-B group (EGIL B-III subtype) ( Figure 3B ), whereas the presence of surface immunoglobulin light chains defines mature B-ALL (EGIL B-IV subtype). Among other B-cell markers, B-I and B-II ALL are often CD24 positive and 4G7 (pro-and pre-B surrogate light chain specific MoAb) positive; 16 surface CD20 and CD22 are variably positive beyond stage B-I; CD13 and CD33 myeloid/cross lineage antigen can be expressed, as well as the CD34 stem cell antigen, particularly in Ph+ (Philadelphia chromosomepositive) ALL (often B-II with CD34, CD38, CD25 and CD13/33), but myeloid-specific CD117 should not be present and can be used to differentiate further between ALL and rare myeloid leukaemias with negative MPO expression. Pro-B ALL with t(4;11)/MLL rearrangements is most often myeloid antigen-positive disease (including expression of CD15). TdT expression is usually lost in B-IV subgroup. T-cell markers are usually not expressed in B-lineage ALL but a CD19+ subset is concurrently CD2+. Loss of surface adhesion molecules has been described.
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Immunophenotype of T-lineage ALL. T-cell ALL constitutes approximately 25% of all adult cases of ALL. T-cell markers are CD1a, CD2, CD3 (membrane and cytoplasm), CD4, CD5, CD7 and CD8. CD2, CD5 and CD7 antigens are markers of the most immature Tcell cells, but none of them is absolutely lineagespecific, so that the unequivocal diagnosis of T-ALL rests on the demonstration of surface/cytoplasmic CD3. In T-ALL the expression of CD10 is quite common (25%) and not specific; CD34 and myeloid antigens CD13 and/or CD33 can be expressed too. Recognized T-ALL subsets are the following: pro-T EGIL T-I (cCD3+, CD7+), pre-T EGIL T-II (cCD3+, CD7+ and CD5/CD2+), cortical T EGIL T-III (cCD3+, Cd1a+, sCD3+/-) and mature-T EGIL T-IV (cCD3+, sCD3+, CD1a-). Finally, a novel subgroup that was recently characterized is represented by the so called ETP-ALL (Early-T Precursor), which shows characteristic immunophenotypic features, namely lack of CD1a and CD8 expression, weak CD5 expression, and expression of at least one myeloid and/or stem cell marker.
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Mixed Phenotype Acute Leukemia. With currently refined diagnostic techniques the occurrence of acute leukemia of ambiguous cell lineage, i.e. mixed phenotype acute leukemia (MPAL) is relatively rare (<4%). 19 These cases express one of the following feature: 1) coexistence of two separate blast cell populations (i.e. T-or B-cell ALL plus either myeloid or monocytic blast cells, 2) single leukemic population of blast cells co-expressing B-or T-cell antigens and myeloid antigens, 3) same plus expression of monocytic antigens. For myelo-monocytic lineage useful diagnostic antigens are MPO or nonspecific esterase, CD11c, CD14, CD64 and lysozyme; for Blineage CD19 plus CD79a, cytoplasmic CD22 and CD10 (one or two of the latter according to staining intensity of CD19) and for T-lineage cytoplasmic or surface CD3. Recognized entities include Ph+ MPAL (B/myeloid or rarely T/myeloid), t(v;11q23;MLL rearranged MPAL, and genetically uncharacterized B or T/myeloid MPAL. Very rare cases express trilineage involvement (B/T/myeloid). Lack of lineage-specific antigens (MPO, cCD3, cCD22) is observed in the ultrarare acute undifferentiated leukemia. In a recent review of 100 such cases, 20 59% were B/myeloid, 35% T/myeloid, 4% B/T lymphoid and 2% B/T/myeloid. Outcome was overall better following ALL rather than AML therapy.
NK Cell ALL. CD56, a marker of natural killer (NK) cell differentiation, defines a rare subgroup of about 3% of adult ALL cases which often display other early T-cell antigens, CD7 CD2 CD5, and sometimes cCD3. 19 True NK ALL is very rare (TdT+, CD56+, other T markers negative, unrearranged TCR genes). 21 This diagnosis rely on the demonstration of early NKspecific CD94 or CD161 antigens.
Differential Diagnosis. With few exceptions, ALL is readily identified by morphological marrow assessment and MFC evaluation, with no need for additional tests, since genetics/cytogenetics and genomics are available at a later stage and cannot be employed for purely diagnostic purposes, even if they add very useful clinical-prognostic information. Differentiation between ALL and AML is initially obtained by excluding reactivity to SBB or MPO stains in ALL cells (<3% positive). On cytochemical evaluation, some rare ALL cases are SBB positive but MPO and chloroacetate esterase are negative. True ALL cases that are immunoreactive to MPO or express detectable levels of MPO mRNA have been described. This can occur in Ph+ ALL and occasionally in T-lineage ALL. 22 Evaluation of CD117 antigen expression should also be carried out. 23 Most ALL cases express the nuclear enzyme Terminal deoxynucleotidyl Transferase (TdT). TdT-negative ALL is uncommonly reported, more in T-ALL, while it is a rule in L3/Burkitt leukemia. Therefore all TdT-negative Bprecursor ALL cases must be thoroughly investigated to exclude other aggressive lymphoid neoplasms with leukemic presentation (blastic mantle cell lymphoma, atypical plasmablastic myeloma, other high-grade lymphomas). 24, 25 Diagnostic Cytogenetics. Cytogenetics represents an important step in ALL classification. Conventional karyotyping can be helpful in the identification of recurrent translocations, as well as gain and loss of gross chromosomal material; however, the major limitation of this technique is that in some cases leukemic cells fail to enter metaphase. However, fluorescence in situ hybridization (FISH) can enable the detection and direct visualization of virtually all investigated chromosomal abnormalities in ALL, with a sensitivity of around 99%. Finally, array-comparative genomic hybridization (array-CGH, a-CGH) and single nucleotide polymorphisms (SNP) arrays can permit the identification of cryptic and/or submicroscopic changes in the genome. Karyotypic changes found in ALL include both numerical and structural alterations which have profound prognostic significance. [26] [27] [28] [29] [30] With these premises in mind, the karyotypic changes that occur in ALL can be roughly subdivided in those associated respectively with a relatively good, intermediate and poor prognosis ( Table 2) . [31] [32] [33] [34] However, it must be kept in mind that the incidence of certain aberrations is very low, and that for some of them, the prognostic impact can be strongly affected by the type and intensiveness of therapy administered. Cytogenetic/Genetic Risk Groups. Among the good prognosis aberrations, it is worth mentioning del(12p) or t(12p)/t(12;21)(p13;q22) in B-lineage ALL, and t(10;14)(q24;q11) in T-ALL. These abnormalities are relatively rare in adults compared with childhood ALL.
Aberrations associated with an intermediate-risk comprise the normal diploid subset plus cases with hyperdiploidy and several other recurrent or random chromosomal abnormalities. Table 2 . Cytogenetics and prognosis in Ph-negative ALL. Two karyotype-related prognostic classifications of Ph-negative ALL, as derived from two recent clinical series (31, 32) . Definition of risk groups is according to the SWOG study, ranging from <30% for the very high risk group to 50% and greater for the favorable subtypes. Some differences are observed in the normal and "other" karyotypic subgroups, which are assigned to the next better category in the SWOG study compared to MRC-ECOG. It is necessary to note that 9p deletions are not always associated with a favorable prognosis. In a study identifying 18 such cases, survival was short and comparable to Ph+ ALL (33).
OS, overall survival; low hyperdiploid: 47-50 chromosomes; high hyperdiploid: 51-65 chromosomes; tetraploid: >80 chromosomes; low hypodiploid: 30-39 chromosomes; near triploid: 60-78 chromosomes; complex: >5 unrelated clonal abnormalities *evaluable N = 1003; 267/1373 (19%) evaluable by cytogenetics/FISH/RT-PCR had Ph+ ALL and were excluded from analysis (5-year OS probability 0.22) **evaluable N = 140; 36 (26%) with Ph+ ALL were excluded from analysis (5-year OS probability 0.08) 1 combined OS probability for favorable/intermediate risk groups 2 patient did not enter CR 3 this group has only 12 subjects grouped as high risk despite 5-year OS probability of 0.47
MRC-ECOG (N = 1366)* SWOG (N = 200)** Cytogenetic risk group
No 37 and IGH rearrangements, including CRLF2. 38 Finally, patients with t(9;22)(q34;q11)or BCR-ABL1 rearrangements or a positive FISH test (Ph+ ALL), t(4;11)(q21;q23) or MLL rearrangements at 11q23, monosomy 7, hypodiploidy/low hypodiploidy (and the strictly related near triploid group) fall into the poor-risk cytogenetic category, with an overall diseasefree survival (DFS) rate of about 25%, or 10% in the case of Ph+ ALL prior to the introduction of tyrosine kinase inhibitors (TKI). [39] [40] [41] [42] Ph+ ALL may constitute 25-50% of CD10+ common or pre-B ALL cases and represent the most frequent abnormality in the adult/elderly, being detected in more than 50% of cases in 6 th decade of life. 43 Secondary chromosome abnormalities in addition to t(9;22)(q34;q11) may worsen the prognosis; 44 however, this is as yet unproven in TKI era. 45 Currently, the most unfavorable group within cases with known genetic/molecular aberration is represented by t(4;11)(q21;q23) + MLL1-rearranged ALL, for which outcome is very poor unless allogeneic transplantation is adopted. 46 Some other karyotypes are unique to specific ALL syndromes. Translocations involving chromosome 8 (MYC gene), such as t(8;14)(q24;q32) (90% of cases), t(8;22)(q24;q11)(10% of cases), and t(2;8) (rarely observed), are virtually present in 100% of cases of mature B-ALL with L3/Burkitt morphology and clonal surface immunoglobulins. Typical cytogenetic aberrations are also found in T-lineage ALL. 47 The most frequent involve 14q11 breakpoints e.g. t(10;14)(q24;q11), t(11;14)(p13;q11), or other. The presence of t(8;14) with breakpoints at q24;q11 (q24;q32 in B-ALL) in T-ALL is associated with a lymphomatous, aggressive presentation. 48, 49 New Genetics and Genomics in ALL. The integration of results of several techniques, i.e. gene expression profiling (GEP), SNP array analysis, and currently next-generation sequencing (NGS), have permitted a better definition of the molecular scenario of ALL and the identification of a constellation of novel mutations; as for the latter, however, caution must be shown, since while the biological role has been elucidated for some, while further investigation is required for others. These findings are detailed below (Tables 3, 4) .
B-lineage ALL: IKZF1
, encoding for the transcription factor Ikaros, is frequently disrupted in BCR/ABL+ ALL (80% of cases). IKZF1 deletions, that can be different in size, are predictors of poor outcome in Ph+ ALL, [50] [51] [52] as well as in non-Ph+ ALL. [53] [54] [55] Deregulated overexpression of CRLF2 (∆−CRLF2), found exclusively in 5-10% B-ALL cases without known molecular rearrangements 56, 57 is usually sustained by two types of aberrations: a rearrangement that involves CRLF2 and the Ig heavy chain locus (IGH@-CRLF2) or an interstitial PAR1 deletion that juxtaposes intron 1 of P2RY8 to the coding region of CRLF2 itself. More rarely, CRLF2 mutations can be detected. ∆-CRLF2 can be detected together with IKZF1 deletion in Ph-negative ALL patients and with JAK mutations (JAK1 or JAK2) or IL7R mutations; furthermore, they are identified in roughly 50% of children with Down syndrome; 55, 58 although some contrasting results have been reported, its presence correlates with an overall poor outcome. 54, 55 By the integration of genome-wide technologies, the "BCR/ABL-like" subgroup has been suggested/identified in both the adult 59, 60 and pediatric populations 61, 62 and it accounts for about 15% of B-ALL cases. This subgroup is characterized by a gene expression signature that is similar to that of BCR/ABL+ patients, frequent detection of IKZF1 deletions and CRLF2 rearrangements and adismal outcome. NGS has revealed the presence of mutations and/or rearrangements activating tyrosine kinases, i.e IGH-CRLF2, NUP214-ABL1 rearrangements, in-frame fusions of EBF1-PDGFRB, BCR-JAK2 or STRN3-JAK2 and cryptic IGH-EPOR rearrangements. 63 The recognition of this subgroup is of relevance, because of the poor prognosis observed. Open issues are represented by difficulty in detecting them with techniques other than gene expression profiling, which is not routinely performed in all centers, and by the fact that there is not a recurrent common lesion underlying the signature identified. With this in mind, it is plausible that the use of TKIs and/or mTOR inhibitors might be of benefit in these patients, as suggested by xenograft models. 64, 65 Hypodiploid ALL, regarded as a poor prognosis group, has been extensively evaluated in pediatric ALL: 66 NGS proved that lesions involving receptor tyrosine kinases and RAS signaling (i.e. NRAS, KRAS, FLT3 and NF1) can be detected in up to 70% of near haploid cases, whereas low hypodiploid cases are characterized by lesions involving members of the Ikaros family, particularly IKZF2, and by TP53 disruptions, that can be identified in 91.2% of these cases. In adult ALL, these cases are characterized by nonrandom TP53 disruption has been also recently evaluated in childhood and adult ALL. In children [68] [69] [70] [71] this is detected in 6.4% and 11.1% of relapsed B-ALL and T-ALL cases, and, in a smaller minority of cases, also at diagnosis. A correlation with poorer outcome has been shown. In adults, TP53 mutations are identified at diagnosis in 8.2% of cases (11.1% T-ALL and 6.4% B-ALL), and are preferentially identified in cases without molecular aberrations, where they are detected in 14% of cases, and are associated with refractoriness to chemotherapy.
Other lesions identified by NGS in B-lineage ALL, are represented by mutations in CREBBP and its paralogue, EP300 (p300), 72 which were identified in the relapse samples and appear to be more frequent in hyperdiploid relapsed cases. 73 Similarly, NT5C2 mutations, which confer increased enzymatic activity on the NT5C2 protein, which normally dephosphorylates nucleoside analogs, such as mercaptopurine, used in consolidation and maintenance therapy, have been described. 74 Results are summarized in Table 3 . T-lineage ALL: In T-ALL, well-recognized aberrations include the T-cell receptor (TCR) gene rearrangements, chromosomal deletions, and focal gene deletions ( Table 4) . [75] [76] [77] [78] [79] [80] [81] [82] [83] Moreover, chromosomal rearrangements can also lead to in-frame fusion genes encoding chimeric proteins with oncogenic properties such as PICALM-MLLT10, NUP214-ABL1 fusion formed on episomes, EML-ABL1, SET-NUP214 fusion and MLL gene rearrangements with numerous different partners. The prognostic significance of these lesions is uncertain.
Furthermore, the ETP subgroup and/or myeloid-like subgroup emerged as a grey zone between AML and T-ALL by applying genome-wide technologies. 18, 84, 85 Initially, the reported incidence of this subgroup was established at around 10% of T-ALL cases; however, with the better recognition of these cases, its frequency is likely to be higher. Immunophenotype is characterized by an early T-cell phenotype and coexpression of at least one myeloid marker, while at the transcriptional level they have a stem-cell like profile with overexpression of myeloid transcription factors (including CEBPA, CEBPB, CEBPD), and a set of micro-RNAs (miR-221, miR-222 and miR-223). NGS has highlighted the presence of mutations usually found in acute myeloid leukemia (IDH1, IDH2, DNMT3A, FLT3 and NRAS), 86 as well mutations in the ETV6 gene. Finally, these cases rarely harbor NOTCH1 mutations. 87 Overall, prognosis is poor in these cases.
A large set of mutations (Table 4 ) has been identified in T-ALL by re-sequencing and NGS: they include NOTCH1, FBW7, BCL11B, JAK1, PTPN2, IL7R and PHF6, beyond those identified in ETPs; some of them have recognized prognostic significance, whereas for others further studies are required. In fact, NOTCH1 and/or FBW7 mutations, which occur in more than 60% and about 20% of cases, respectively, are usually associated with a favorable outcome. In the light of this, a prognostic model has been recently proposed, defining as low-risk patients those who harbor NOTCH1 and FBW7 mutations, and as high risk those without these mutations or with lesions involving RAS/PTEN. 83, [88] [89] [90] [91] At variance, JAK1 mutations, which increase JAK activity and alter proliferation and survival have been associated with chemotherapy refractoriness and should be considered as poor prognostic markers. [92] [93] [94] Finally, another group of mutations/lesions is possibly involved in leukemogenesis, but their prognostic impact is either unknown or absent. They include: 1) BCL11B lesions, which can induce a developmental arrest and aberrant self-renewal activity; 95, 96 2) PTPN2 -a negative regulator of tyrosine kinases-, mutations, often detected in TLX1 overexpressing cases, T-ALL, NUP214-ABL+ patients and JAK1 mutated cases; 97, 98 3) mutations in IL7Ralpha, that lead to constitutive JAK1 and JAK3 activation and enhancement of cell cycle progression; 99,100 4) PHF6 mutations; 101,102 5) mutations in PTPRC, encoding the protein tyrosine phosphatase CD45, usually detected in combination with activating mutations of IL7R, JAK1 or LCK, and associated with downregulation of CD45 expression; 103 6) mutations in CNOT3, presumed to be a tumor suppressor; 7) mutations of RPL5 and RPL10, which impair ribosomal activity. 104 Lastly, similarly to what is observed in relapsed B-ALL, NT5C2 mutations.
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Concluding Remarks. Due to the reviewed evidence and the complexity of all the issues at play, it is recommended that adult patients with ALL should be treated within prospective clinical trials, which is the best way to ensure both diagnostic accuracy and therapeutic efficacy. In the context of a modern riskand subset-oriented therapy, the early diagnostic workup is of the utmost importance and therefore needs to be carried out by well trained and highly experienced personnel (Figure 4) . As a first step, it is mandatory to differentiate rapidly Ph+ from Ph-ALL and to distinguish between major immunophenotypic subsets in the latter group. The remaining diagnostic elements are available at a later stage and permit a proper identification and treatment of the several disease and risk entities. Ongoing research will permit the further definition of novel subgroups with prognostic significance. To confirm diagnosis and obtain clinically useful information, it is necessary to 1) differentiate rapidly Ph-positive ALL from Ph-negative ALL in order to allow an early introduction of tyrosine kinase inhibitors in the former subset, 2) distinguish between different clinicoprognostic Ph-ALL subsets, and 3) clarify diagnostic issues related to the application of targeted therapy and risk-/minimal residual disease (MRD)-oriented therapy. The early diagnostic phase must be completed within 24-48 hours. Additional test for cytogenetics/genetics, genomics and MRD rely on collection, storage and analysis of large amounts of diagnostic material, and are usually available at later timepoints during therapy, however before taking a decision for allogeneic stem cell transplantation (SCT). All this requires a dedicated laboratory, and is best performed within a prospective, well coordinated clinical trial.
